LMTK3 and breast cancer: Consistent with this hypothesis, we found that knockdown of MIR2052HG using a pooled ASO in human ER-positive CAMA-1 breast cancer cells resulted in a dramatic decrease of LMTK3 expression (Fig. 1a).